�

�

�

�

�
�
�

�
�
�

�

�

�
�

3 m 6 m 12 m 18 m

Follow-upFollow-up

PDT-1 PDT-2 (if lesions remain)

�
�
�

�

�

�

�

0

10

20

30

40

50

60

70

80

90

100

after 1. PDT after 1. and 2. PDT

C
om

pl
et

el
y 

C
le

ar
ed

 P
at

ie
nt

s 
[%

]

Patient Complete Response [FAS]
BF-200 ALA (n=55) Placebo (n=32)

0

10

20

30

40

50

60

70

80

90

100

after 1. PDT after 1. and 2. PDT

C
om

pl
et

el
y 

C
le

ar
ed

 L
es

io
ns

 [%
]

Lesion Complete Response [FAS]
BF-200 ALA (n=298) Placebo (n=173)

�

�

�

Skin surface Hyperpigmentation Hypopigmentation

Mottled pigmentation Scarring Atrophy

0.00

0.20

0.40

0.60

0.80

1.00

1.20

1.40

0.00

0.10

0.20

0.30

0.40

0.50

0.60

0.70

0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90

0.00

0.10

0.20

0.30

0.40

0.50

0.60

0.70

0.00

0.10

0.20

0.30

0.40

0.50

0.00

0.10

0.20

0.30

0.40

0.50

0 12 26 52

Weeks after last PDT

* *

*

*
*

*

*
*

* *
*

*
*

*
*

*
*

0 12 26 52

Weeks after last PDT

0 12 26 52

Weeks after last PDT

0 12 26 52

Weeks after last PDT

0 12 26 52

Weeks after last PDT

0 12 26 52

Weeks after last PDT

Im
p

a
ir

m
e

n
t
 s

c
o

r
e

 (
0

-
3

)

Im
p

a
ir

m
e

n
t
 s

c
o

r
e

 (
0

-
3

)

Im
p

a
ir

m
e

n
t
 s

c
o

r
e

 (
0

-
3

)

Im
p

a
ir

m
e

n
t
 s

c
o

r
e

 (
0

-
3

)

Im
p

a
ir

m
e

n
t
 s

c
o

r
e

 (
0

-
3

)

Im
p

a
ir

m
e

n
t
 s

c
o

r
e

 (
0

-
3

)

±

�
�
�
�

Follow-up


	FC17PosterBiofronteraDirschkaPhotodynamicTherapyActinicKeratosis.pdf